Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Intersection of Two Public Health Problems: Under Treatment of Pain and Abuse and Misuse of Pain Medications Richard C. Dart, MD, PhD Director, Rocky.

Published byTracy Cornett Modified over 9 years ago

Similar presentations

Presentation on theme: "The Intersection of Two Public Health Problems: Under Treatment of Pain and Abuse and Misuse of Pain Medications Richard C. Dart, MD, PhD Director, Rocky."— Presentation transcript:

1 The Intersection of Two Public Health Problems: Under Treatment of Pain and Abuse and Misuse of Pain Medications Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Professor, University of Colorado 1

2 Outline Worldwide Challenges RADARS System Data from US and Canada Framework for understanding and intervention Discussion 2

3 Opioid Consumption (ME/capita), 2010 3

4 Consumption of Prescription Opioids, 1964 - 2012 > 800 morphine equivalents/capita! http://www.painpolicy.wisc.edu/global 4

5 More Drug Production = More Drug Abuse But - the Slope Varies by Drug 5 Dasgupta N et al. Drug Alcohol Depend. 2006;82(2):135-142.

6 Drug-Poisoning and Opioid Analgesic Poisoning Death: United States, 1999-2011 http://www.cdc.gov/nchs/data/databriefs/db166.htm 30,000 deaths 6

7 Opioid Analgesic Poisoning Death, by Age Group, United States, 1999-2011 http://www.cdc.gov/nchs/data/databriefs/db166.htm 7

8 What is the RADARS ® System? 8 DHHA RMPDC RADARS System History –2002, Purdue Pharma –2006, Denver Health and Hospital Authority –Rocky Mountain Poison and Drug Center –Denver Public Hospital for 150 years –State sanctioned independent authority. Conflict of Interest Statement Most manufacturers of prescription opioids or stimulants subscribe to RADARS System. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Subscribers receive information, but do not participate in developing the System, data collection, or analysis of the data. They do not have access to the raw data. Employees are prohibited from personal financial relationships with any company.

9 Drug Transactions Criminal Justice 260 agency; 49 states 145,090 cases with 146,786 opioid mentions Illicit Market Price StreetRx.com Users/Buyers, 50 states 8,441 price entries for an opioid New Initiates College Survey 2000 students, 50 state 3,564 cases with 11,871 opioid mentions Entering Treatment SKIP 109 practices, 45 states 10,214 cases with 64,678 opioid mentions Acute Health Events 49 Poison centers 46 states 456,610 cases 491,874 opioid mentions Entering Treatment Opioid Tx Program 66 programs; 34 states 41,031 cases with 183,573 opioid mentions Mosaic Surveillance of Prescription Drug Abuse - 2013 Web Monitoring > 150 million sites monitored > 35,000 posts coded for analysis StreetRx 9

10 Abuse Deterrent Formulations 10

11 Swallow Misuse/Abuse Chew Crush Snort Inject Abuse Deterrent Formulations Population of People with Addiction Risk Exposed to Opioid 11 Currently Approved ADFs Can ADFs Minimize Progression?

12 Mosaic Surveillance on Opana ER and OxyContin Poison Center Program Treatment Programs COMBINED Drug Diversion Program StreetRx Population Price per milligram 12

13 Mosaic Surveillance on Opana ER and OxyContin Poison Center Program Treatment Programs COMBINED Drug Diversion Program StreetRx Population URDD URDD – Unique Recipients of Dispensed Drug 13 URDD PopulationURDD

14 Drug Diversion Program ER Oxymorphone Diversion Cases January 2011 through June 2013 14 Before Reformulation After Reformulation

15 Unanswered Questions 15

16 Drug Diversion Program ER oxymorphone diversion cases by state and time period January 2011 through June 2013 16

17 Squeezing the Balloon National Survey of Drug Use and Health, 2012 Reformulated OxyContin 17

18 Oxycodone ADF in US and Canada 18 Formulation United StatesCanada Number reports Median Price/mg, US Dollar (range) Number reports Median Price/ mg, Canadian Dollar (range) Crushable “Old OxyContin” Apo-Oxycodone CR (imprint APO OCD) 87 1.00 (0.15 – 16.80) 4 2.50 (1.00 – 6.00) OxyContin ® 137 1.00 (0.01 – 12.00) 43 1.00 (0.03 – 16.00) Co-Oxycodone CR (imprint OXY CR) 51 1.00 (0.05 – 22.00) 3 1.00 (1.00 – 2.00) Teva-Oxycodone CR (imprint N) 8 0.38 (0.10 – 3.75) 0NR Median2831.00501.00 Abuse Deterrent “New OxyContin” Oxycodone ER (OxyContin in US, OxyNEO in Canada) 364 0.70 (0.03 – 10.00) 23 0.63 (0.20 – 4.00) Median3640.70230.63

19 Opioid Analgesic Trends in the United States, 2014 Q1 Poison Center Program Total Drug Diversion Program Total College Survey Program Total Survey of Key Informant Patients Total Opioid Treatment Program Total Analgesic group: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol 19

20 Opioid Analgesic Trends in the United States, 2014 Q1 Poison Center Program TotalIR + ER College Survey Program Total IR + ER Analgesic group: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol Opioid Treatment Program Total IR + ER Drug Diversion Program Total IR + ER Survey of Key Informant Patients TotalIR + ER 20

21 What Changed? Prescription Monitoring Plans (49 states) Law Enforcement Efforts (Federal, State, Local) – Drug Diversion Investigators – Drug Takeback Days Abuse Deterrent Formulations Professional Education and Training/Guidelines Public Education FDA Risk Evaluation and Mitigation Strategy (REMS) Rescheduling of Vicodin Improved access to substance abuse treatment 21

22 VTVT VAVA SCSC HIHI MIMI NYNY RIRI ILIL PAPA TXTX CACA MAMA OKOK WVWV NVNV Prescription Monitoring Plans CTCT AZAZ FLFL FKYLFKYL LALA IAIA MNMN KSKS IDcIDc NMNM MSMS COCO OHOH OROR ALAL TNTN UTUT WYWY MEME SDSD WIWI NDND ALAL ININ NCNC Conceptual Framework for Understanding Prescription Analgesic Abuse and Potential Interventions 0 0 0 0 0 0 0 0 0 00 20101970 19801990 2000 ADFFL ER/LA REMS TIRF REMS WA/NY/ACEP Rx Guidelines Natl Drug Take Back HC-APAP Tramadol 22 H H H H H H H H H VA 5 th VS Opioids Chronic Noncancer Pain Papers, AAPM, APS, AGS, BPS, AAFP, >21 org OC “Crushable”

23 DORA Issues 600 Notifications on Potential Doctor-Shopping October 31, 2014 DENVER - Over 600 prescribers and pharmacies in the State are receiving a notification today from the Colorado Prescription Drug Monitoring Program (PDMP) that a patient they treat obtained potentially dangerous amounts of controlled substances from multiple prescribers and pharmacies. In one instance, a patient obtained prescriptions from 11 different prescribers and 10 different pharmacies within 30 days…. Another person obtained over 1,600 pills of oxycodone and hydrocodone from multiple prescribers and dispensers in one month. 23

24 Population with Addiction Risk ↓ Exposed to Opioid Swallow Misuse/Abuse Chew Crush Snort Inject A Framework for Understanding Rx Drug Abuse 24 InterventionEffect on Pain Tx Prescriber Guidelines/ Training+/- Prescription Monitoring Plans+/- Abuse Deterrent Formulations+ Law Enforcement- Public Education+/- Drug Take-Back Programs+ ADF – Crush resistant difficult to chew ADF – Crush resistant ADF – Crush resistant, capsaicin ADF – Naloxone, Naltrexone Substance Abuse Treatment

25 Conclusions Opioid analgesics remain a major threat in developed countries. Death rates plateauing, led by young adults. Hints about effective interventions are available. – ADFs are one, but will not be effective alone Multi-pronged efforts seem more likely to be effective Need new approach to drug scheduling by formulation and not by API Substance abuse treatment is an important component of successful interventions 25

Download ppt "The Intersection of Two Public Health Problems: Under Treatment of Pain and Abuse and Misuse of Pain Medications Richard C. Dart, MD, PhD Director, Rocky."

Similar presentations

MAPS Michigan Automated Prescription System. Exempt From Reporting Medications administered directly to patients. Dispensing of up to a 48 hour supply.

MAPS Michigan Automated Prescription System. Exempt From Reporting Medications administered directly to patients. Dispensing of up to a 48 hour supply.
Opioid Misuse: A Health Plan Perspective Marcus Thygeson, MD, MPH SVP, Chief Health Officer Blue Shield of California.

Opioid Misuse: A Health Plan Perspective Marcus Thygeson, MD, MPH SVP, Chief Health Officer Blue Shield of California.
The purpose of this overview is to update the facts pertaining to the possibility of upward trends related to heroin trafficking and/or abuse in the Commonwealth.

The purpose of this overview is to update the facts pertaining to the possibility of upward trends related to heroin trafficking and/or abuse in the Commonwealth.
Prescription Opioid Overdose & Misuse in Oregon Mel Kohn, MD MPH Public Health Director and State Public Health Officer Oregon Health Authority Oregon.

Prescription Opioid Overdose & Misuse in Oregon Mel Kohn, MD MPH Public Health Director and State Public Health Officer Oregon Health Authority Oregon.
CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.

CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.
National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.

National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.
Lock Your Meds BE AWARE. DON'T SHARE.. Your Home Medicine Cabinet: Does it look like this?

Lock Your Meds BE AWARE. DON'T SHARE.. Your Home Medicine Cabinet: Does it look like this?
Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.

Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.
Recovery Housing and The National Drug Control Strategy David K. Mineta Deputy Director, Demand Reduction Office of National Drug Control Policy (ONDCP)

Recovery Housing and The National Drug Control Strategy David K. Mineta Deputy Director, Demand Reduction Office of National Drug Control Policy (ONDCP)
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.

John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.

Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
Lock Your Meds BE AWARE. DON'T SHARE. Sponsored by.

Lock Your Meds BE AWARE. DON'T SHARE. Sponsored by.
Serving our community by improving health The Addiction Crisis November 2014.

Serving our community by improving health The Addiction Crisis November 2014.
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.

Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse.

1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse.
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.

Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
FDA REMS Program REMS: Risk Evaluation & Management Strategy

FDA REMS Program REMS: Risk Evaluation & Management Strategy
Drug Diversion, Sources, and Extent: United States Case Study Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist Pain & Policy Studies.

Drug Diversion, Sources, and Extent: United States Case Study Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist Pain & Policy Studies.

Similar presentations

Ads by Google